Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-09-22 超人明白纯真

审稿速度:6.0
偏重的研究方向：乳腺癌
经验分享：
Handling Editor: Shengtao Zhou
Received date: 17 Mar 2021
Editorial assignment start date: 18 Mar 2021
Independent review start date: 24 May 2021
Interactive review activated date: 03 Aug 2021
Review finalized date: 24 Aug 2021
Final validation date: 21 Sep 2021
昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！

81 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2022-05-05 ms7000000322107334

偏重的研究方向：宫颈癌
经验分享：有没有人跟我一样1个半月了还在editorial assignment

172 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2020-07-23 heli0118

审稿速度:2.0
经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020#肿瘤#

763 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-06-07 机智肝帝武运昌隆欧洲呆

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！

153 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-01-14 cyy0125

第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。

133 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2022-02-15 ms6000000251788979

偏重的研究方向：乳腺癌
经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？

91 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-07-26 ms7000001962210336

请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？

56 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-09-02 ms8000001148126855

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：乳腺癌
经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急

73 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2021-04-21 1467c3d2m05暂无昵称

审稿速度:3.0 | 投稿命中率:50.0
经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。

71 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=1053754, encodeId=22d91053e5427, content=审稿速度:6.0 偏重的研究方向：乳腺癌 经验分享： Handling Editor: Shengtao Zhou Received date: 17 Mar 2021 Editorial assignment start date: 18 Mar 2021 Independent review start date: 24 May 2021 Interactive review activated date: 03 Aug 2021 Review finalized date: 24 Aug 2021 Final validation date: 21 Sep 2021 昨晚终于接收了，从投到接收半年左右，希望大家都顺顺利利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=超人明白纯真, createdTime=Wed Sep 22 12:28:23 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217160, encodeId=64ad121e16020, content=偏重的研究方向：宫颈癌 经验分享：有没有人跟我一样1个半月了还在editorial assignment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1875413047, createdName=ms7000000322107334, createdTime=Thu May 05 20:51:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804175, encodeId=0ca18041e5f8, content=审稿速度:2.0 经验分享：运气很好，今天接到接受邮件，杂志效率高，用时不到2个月。以下为投稿过程，供大家参加，祝大家多多发文章。Received date: 28 May 2020 assignment start date: 29 May 2020 Independent review start date: 02 Jun 2020 Interactive review activated date: 29 Jun 2020 Review finalized date: 20 Jul 2020 Final validation date: 21 Jul 2020<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=763, replyNumber=20, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Jul 23 19:51:02 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971577, encodeId=22049e15770a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：听说这个杂志现在已经明确说明不收无验证的纯生信文章，3月投了一篇，有一丢丢创新性，4月中了，是真的搭上末班车，lucky。。 2021-03-09 投稿frontiers in molecular bioscience，initial validation 2021-03-10 editorial assignment 2021-03-15 建议转投 2021-03-16 同意转投至frontiers in oncology 2021-03-31 independent review 2021-04-12 interactive review，大修，我感觉editor就是搞我，一个审稿人接收，一个小修，他给我大修，好在两个审稿人都很nice 2021-04-15 大修修回 2021-04-15 一位审稿人秒同意发表 2021-04-16 第二位审稿人同意发表，review finalized 2021-04-20 accepted 可能是因为过了一个周末，有所延迟 2021-04-22 付款 2021-05-05 开始排版 2021-05-10 收到proof 2021-05-11 修回proof 2021-05-21 published 待我弄点湿实验，再回来灌！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Mon Jun 07 17:48:45 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916575, encodeId=b0859165e533, content=第一次投稿，12.24投稿01.03显示independent review，5天前显示review is ongoing，今天看显示review is ongoing从your manuscript has been submitted successfully的下边移到了上边。有没有出现这种情况的，还请大神解答。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Cpnic8kMq93U2vjU6icFyPIUX8SjgbBADbXbB8bpUryv8ic0uP0YbHrQhEezLxnIdAknUc2zQfdvEEhHjUsaficDAg/132, createdBy=514e2548962, createdName=cyy0125, createdTime=Thu Jan 14 16:52:51 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193722, encodeId=c51c1193e2210, content=偏重的研究方向：乳腺癌 经验分享：一拒、一小修、一大修，编辑给了四天时间修改，没说是大修还是小修，我已经提交修改了，有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea585428031, createdName=ms6000000251788979, createdTime=Tue Feb 15 20:01:52 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002871, encodeId=be0b10028e1b3, content=请问Review is ongoing 消失后在Your manuscript has been submitted successfully上多出了一行You will be contacted as soon as the editor comments or reviewers' reports are ready.这种情况是审稿结论有争议嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210830/a03dcbc0f17442e3aee6d30289c4192a/7b685b39b1cd4bc7a3a662e16908e6db.jpg, createdBy=b7d05519639, createdName=ms7000001962210336, createdTime=Mon Jul 26 22:54:12 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013721, encodeId=9c821013e219b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：两个审稿人都endorse了，编辑一直没反应，第九天了，焦急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=25c75516491, createdName=ms8000001148126855, createdTime=Thu Sep 02 10:57:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959212, encodeId=b35695921224, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：小弟最近投的frontier in oncology杂志刚被录用，现在涉及到交版面费的问题，不是很懂，想请教一下交过的大佬们，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4d85142519, createdName=1467c3d2m05暂无昵称, createdTime=Wed Apr 21 22:57:05 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212552, encodeId=3d641212552d3, content=请问下大家，Initial Validation状态一个礼拜了，正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=554c5533347, createdName=樂獅, createdTime=Tue Apr 19 15:32:11 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2022-04-19 樂獅

请问下大家，Initial Validation状态一个礼拜了，正常吗

73 17

展开17条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务